8-K - Aspire Biopharma Holdings, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Securities Issuance

Financing

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement. Exchange Agreements On January 1, 2026, the Company entered into Exchange Agreements (the “Exchange Agreements”) w

Material Agreement

$1.8M$3.0M

Source Document

2.03

. Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 10.1 Form of Exchange Agreement 104 Cover Page Interactive Data File (embedded with the

Financing

3.02

. Unregistered Sales of Equity Securities. The information set forth under Item 1.01 above of this Current Report on Form 8-K is incorporated by reference in th

Securities Issuance

Exhibits (2)

10.1

EX-10.1

8-K